Targeting CD30 in patients with Hodgkin lymphoma Journal Article

Authors: Kumar, A.; Pileri, S.; Younes, A.; Engert, A.
Article Title: Targeting CD30 in patients with Hodgkin lymphoma
Abstract: The introduction of multi-agent chemotherapy for the treatment of Hodgkin lymphoma is one of the major breakthroughs in clinical oncology. Treatment with multi-agent chemotherapy and improved radiation methods has significantly improved the chance of curing these patients from less than 5% in 1963 to about 80% at present. However, there is still a substantial need to improve current treatment approaches particularly for elderly patients or those with relapsed and refractory disease. Cured patients unfortunately are at high risk for late side effects including second malignancies, cardiac toxicity, infertility, and fatigue. Thus, there is a clear need for new and safer drugs that are more selective in targeting the malignant Hodgkin and Reed-Sternberg (HRS) cells in this disease while sparing normal tissues. © Springer Nature Switzerland AG 2020.
Keywords: autologous stem cell transplantation; hodgkin lymphoma; anaplastic large cell lymphoma; brentuximab vedotin; john cunningham virus
Journal Title: Hematologic Malignancies
ISSN: 2197-9766
Publisher: Springer  
Date Published: 2020-01-01
Start Page: 381
End Page: 393
Language: English
DOI: 10.1007/978-3-030-32482-7_22
PROVIDER: scopus
Notes: Chapter 22 in "Hodgkin Lymphoma - A Comprehensive Review. 3rd ed" (ISBN: 978-3-030-32481-0) -- Export Date: 1 June 2020 -- Source: Scopus
Citation Impact
MSK Authors
  1. Anita Kumar
    67 Kumar
  2. Anas Younes
    248 Younes
Related MSK Work